Share price: 104.00p

Issue of Equity

2nd May 2017

Further to the announcement made on 13th May 2014, regarding the acquisition of iS Healthcare Dynamics (“iS”), the Company today announces that the final deferred consideration payments to the vendors of iS have now been settled in full.

To part satisfy the deferred consideration the Company has applied for the admission of 403,903 new ordinary shares of 10 pence each in the Company (“New Ordinary Shares”) to be admitted to trading on AIM.  This Admission is expected to occur on 8 May 2017.

Following the issuance of these new Ordinary Shares, Cello’s issued share capital will consist of 104,094,797 ordinary shares of 10 pence each (“Ordinary Shares”). The Company holds 453,000 Ordinary Shares in treasury. The total number of current voting rights in the Company is therefore 103,641,797 Ordinary Shares.

The above figure (103,641,797 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

2 May 2017

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Cenkos Securities

0207 397 8900

Bobbie Hilliam

Harry Pardoe

Contact Us

Dianna Hillier

Dianna.Hillier@cellohealth.com

Phone 020 7812 8468

Address

Cello Health plc

Queens House

8-9 Queen Street

London

EC4N 1SP

Registered Office

Queens House

8-9 Queen Street

London

EC4N 1SP

Company Registered

in England no.05120150